Pharmaceutical giant Eli Lilly announced Tuesday its plans to acquire Centessa Pharmaceuticals through a massive $6.3 billion transaction, marking a significant expansion in the company’s therapeutic portfolio.
The acquisition is specifically designed to bolster Lilly’s capabilities in developing innovative treatments for sleep-wake disorders, a growing area of medical concern affecting millions of Americans.
The deal represents one of the larger pharmaceutical acquisitions announced this year, highlighting the industry’s continued focus on expanding treatment options for neurological and sleep-related conditions.
